News Waltz dances into direct-to-employer sales of obesity drugs Waltz Health is planning to disrupt the weight-loss therapy market in the US with a new direct-to-employer sales channel.
Market Access FT Summit: How Is U.S. Policy Reshaping the UK and EU Pharma... For the Financial Times (FT) Global Pharma & Biotech Summit in London 2025, pharmaphorum is providing coverage courtesy of NAVLIN Daily.
Market Access Lilly EVP: VPAG Deadline Probably Postponed Another Two Week... For the Financial Times (FT) Global Pharma & Biotech Summit in London 2025, pharmaphorum is providing coverage courtesy of NAVLIN Daily.
News Queer Eye's Tan France to front Lilly obesity campaign Eli Lilly has enlisted the aid of Tan France of US makeover show Queer Eye to change the narrative about obesity in a new campaign.
News Novo, Lilly sign MFN pricing deal with Trump administration The pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs for diabetes and obesity has arrived.
News Lilly reports 20% weight loss with amylin-targeting drug Eli Lilly has raised the stakes in the obesity market with positive midstage data for its amylin-targeting drug eloralintide.
News Remepy's hybrid Parkinson's therapy poised for phase 3 Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
